Advertisement
Canada markets closed

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7320
    -0.0000 (-0.01%)
     

  • CRUDE OIL

    83.46
    +0.10 (+0.12%)
     

  • Bitcoin CAD

    90,899.23
    -374.59 (-0.41%)
     

  • CMC Crypto 200

    1,428.98
    +14.22 (+1.00%)
     

  • GOLD FUTURES

    2,337.20
    -4.90 (-0.21%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,709.25
    +102.50 (+0.58%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    0.00 (0.00%)
     

  • CAD/EUR

    0.6837
    +0.0001 (+0.01%)
     

Why Satsuma Pharmaceuticals Stock Is Plummeting Today

Keith Speights, The Motley Fool
·2 min read
Why Satsuma Pharmaceuticals Stock Is Plummeting Today

Shares of Satsuma Pharmaceuticals (NASDAQ: STSA) are plunging today, down 74.8% as of 11:17 a.m. EDT, after the company announced that investigational drug STS101 failed to meet the primary endpoints in a phase 3 study in treating migraine. Neither the 3.9 mg nor the 5.2 mg dose of the nasal powder achieved statistically significant improvement in the key symptoms of migraine at two hours after administration. Satsuma CEO John Kollins said that the company was "surprised and disappointed" by these results.

Continue reading